Clinical Trial Update: A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants [Phase 3]

View source ↗

Summary

AbbVie has completed a Phase 3 trial of ABBV-444 Drops in adults with Dry Eye Syndrome, with results posted evaluating symptom relief and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndrome

Drugs mentioned

• ABBV-444 Drops

Snippet

Sponsor: AbbVie | Conditions: Dry Eye Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2024-10-15